Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: Genotypic and phenotypic analyses of study GS-96-408

Journal of Acquired Immune Deficiency Syndromes

Volumn 27, Issue 5, 2001, Pages 450-458

  Miller, Michael D ^a   Margot, Nicolas A ^a   Lamy, Patrick D ^a   Fuller, Michael D ^a   Anton, Kristin E ^a   Mulato, Andrew S ^a   Cherrington, Julie M ^b  

^a GILEAD SCIENCES   (United States)

^b SUGEN INC   (United States)

Author keywords

Adefovir; HIV; Resistance; Tenofovir

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; PLACEBO; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 0035881021     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200108150-00005     Document Type: Article

References (33)

1. Drug resistance and its implications in the management of HIV infection
2. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro
3. In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA)
4. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA
5. Identification of a mutation of codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine
6. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase
7. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89
8. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy
9. K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine
10. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro
11. Potential mechanism for sustained antiretroviral efficacy of AZT/3TC combination therapy
12. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
13. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy
14. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy
15. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
16. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay
17. New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS-antiviral activity
18. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)
19. Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex
20. Human immunodeficiency virus reverse transcriptase and protease sequence database
21. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)
22. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
23. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy
24. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors
25. Anti-HIV activity profile of tenofovir (PMPA) against a panel of nucleoside-resistant clinical samples
26. Phenotypic susceptibility to adefovir dipivoxil in clinical samples with defined RT genotypic resistance patterns
27. Mutations in the reverse transcriptase genome of HIV-1 isolates derived from subjects treated with didanosine and stavudine in combination
28. D4T based combination therapy selects for "ZDV like" HIV-1 resistance mutations in ZDV naive adult patients
29. Zidovudine resistance associated mutations can be selected in patients receiving long term exposure to stavudine
30. Patterns of HIV drug resistance in routine clinical practice: A survey of almost 12000 samples from the USA in 1999
31. Tenofovir disoproxil fumarate (TDF) for the treatment of antiretroviral experienced patients. A double blind, placebo-controlled study
32. Anti-HIV responses and development of RT mutations in antiretroviral-experienced patients adding tenofovir DF Therapy: 48 Week genotypic analysis of study 902
33. Tenofovir (PMPA) is less efficiently removed through pyrophosphorolysis and dinucleotide polyphosphate synthesis than zidovudine (AZT) by HIV-1 wild-type RT and RT mutants